Researchers improve how a peptide can be delivered to the diseased heart tissue of mice via nanotechnology

October 31, 2014 by Tracie White, Stanford University Medical Center

School of Medicine researchers have developed a new formula for delivering the therapeutic peptide apelin to heart tissue. The delivery system, which dramatically increases the peptide's stability, shows promise for treating heart disease in humans, the researchers said.

Mice with induced and failure that were given apelin through the new showed significant improvement, said Jayakumar Rajadas, PhD, founder and director of the school's Biomaterials and Advanced Drug Delivery Laboratory.

A paper describing the findings was published online Oct. 13 in Biomaterials.

"This is a very important development in the field of cardiovascular therapeutics," said Rajadas, a senior author of the paper, who is also assistant director of the cardiovascular pharmacology division of the Stanford Cardiovascular Institute. The lead author is postdoctoral scholar Vahid Serpooshan, MD, PhD.

The heart condition known as hypertrophy, which is commonly attributed to sudden death in athletes, is generally a hereditary disease that is triggered by cardiac stress due to extreme exercise, hypertension, valve malfunction or ventricular infarction.

Short plasma half-life of apelin

G-protein-coupled receptors on the surface of function as stress sensors. They bind with the apelin peptide in a process crucial to preventing cardiac dysfunction. When the heart is overloaded by various stressors, the body produces more apelin for this process. Although it's unclear why, patients with hypertrophy have low levels of apelin, which are further used up with added stressors, such as hypertension.

In a treatment model similar to giving insulin to diabetes patients, physicians have attempted to treat these with doses of apelin. The therapeutic agent is delivered intravenously to the cardiovascular tissue, but because of its short half-life—the drug is quickly eliminated from the blood plasma—the success of this treatment has been limited.

"This approach turned out to be challenging since apelin has a very short half-life of about eight minutes in the blood and hence limited bioavailability," Rajadas said.

Rajadas, an expert in the field of nanotechnology—the engineering of functional systems at a molecular scale to create "nanostructures"—saw a potential for improving the delivery system of the peptide to the heart tissue. Nanotechnology has been used to stabilize therapeutic agents in the body and target them to specific tissues for the past 10 years, he said. In this case, the idea was to protect the quickly degrading apelin peptides with large, stable molecules during their transport to the .

The Trojan horse

The research team developed a novel technique to increase the stability of the fragile apelin peptides by protecting them with a lipid cover that Rajadas calls the "Trojan horse" method of delivery. The liposome "nanocarriers" encapsulate the apelin and sneak it through the blood to the heart tissue.

The resulting apelin "nanobullets," as the researchers refer to them, were then delivered through the blood system to the cardiovascular tissue of mice with induced hypertrophic heart conditions. The theory was that the apelin would not be released until it was near the heart tissue.

When researchers delivered the nanoparticle preparation in two shots over 14 days to the mice, the animals showed dramatic recovery compared with those in the control group, which only received saline or treatment with uncovered apelin, Rajadas said.

"Apelin in this form could eventually be used as treatment for humans delivered as a shot rather than intravenously as in the past," said Rajadas. "The idea is that regular monthly or bimonthly shots could lesson symptoms."

Explore further: Research suggests ELABELA hormone plays a key role in endoderm and heart development

Related Stories

New class of drug targets heart disease

September 17, 2013

(Edmonton) Researchers at the University of Alberta have developed a synthetic peptide that could be the first in a new class of drugs to treat heart disease, high blood pressure and diabetes.

Apelin hormone injections powerfully lower blood sugar

November 4, 2008

By injecting a hormone produced by fat and other tissues into mice, researchers report in the November Cell Metabolism that they significantly lowered blood sugar levels in normal and obese mice. The findings suggest that ...

Understanding the APJ Receptor Binding Site

June 1, 2010

( -- Apelin is a recently discovered peptide that binds to the apelin (or APJ) G-protein-coupled receptor. Apelin-13 (NH2-QRPRLSHKGPMPF-COOH), one of several cleavage products of the proprotein form of the apelin ...

Novel hormone essential for heart development discovered

December 6, 2013

Scientists at A*STAR's Institute of Medical Biology (IMB) and Institute of Molecular and Cellular Biology (IMCB) have identified a gene encoding a hormone that could potentially be used as a therapeutic molecule to treat ...

Recommended for you

Coffee-based colloids for direct solar absorption

March 22, 2019

Solar energy is one of the most promising resources to help reduce fossil fuel consumption and mitigate greenhouse gas emissions to power a sustainable future. Devices presently in use to convert solar energy into thermal ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.